Drug
Ranibizumab
Ranibizumab: highest development phase Post-Market, developed by Novartis, Roche, Stada Arzneimittel. 4 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Novartis, Roche, Stada Arzneimittel
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ranibizumab NCT01223612 | Post-Market | Diabetic Retinopathy |
| Ranibizumab NCT03805100 | Phase 3 | Macular Degeneration |
| Ranibizumab NCT06847542 | Phase 3 | Neovascular Age-related Macular Degeneration |
| Ranibizumab NCT01840410 | Phase 3 | Choroidal Neovascularization (CNV) |
Latest
No recent events.
Follow Ranibizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.